We’ve made some changes to improve our site’s navigation.

Learn More

AstraZeneca PLCAZN:LSE

3,250.5
4.00 / 0.12%
1.59m
21.15%
0.3259
Close in GBXToday's changeShares traded1 year changeBeta
As of Jun 18 2013 16:58 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Jun 14, 2013, the consensus forecast amongst 27 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy1
Outperform3
Hold16
Underperform5
Sell2
No opinion0

Research Reports

Datamonitor
76 pages, 18 Jun 2013
S&P Capital IQ – STARS Reports
10 pages, 15 Jun 2013
Reuters Investment Profile
12 pages, 15 Jun 2013
Reuters Investment Profile
12 pages, 15 Jun 2013
Charles Stanley Securities
2 pages, 14 Aug 2007

Share price forecast

Share price forecast information is not available for AstraZeneca PLC. View Full Financials

Dividends

In 2012, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 25 analysts covering the company expect dividends of 2.80 USD for the upcoming fiscal year, maintaining dividends from this year. View Full Financials

Div growth (TTM)0.00%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 25, 2013, AstraZeneca plc reported 1st quarter 2013 earnings of 1.41 per share. This result exceeded the 1.32 consensus of the 10 analysts covering the companyand under-performed last year's 1st quarter results by 22.10%.
The next earnings announcement is expected on Aug 01, 2013. View Full Interim Financials

Average growth rate-5.77%

AstraZeneca plc reported annual 2012 earnings of 6.41 per share on Jan 31, 2013. View Full Annual Financials

Average growth rate+8.34%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

AstraZeneca PLC had 1st quarter 2013 revenues of 6.39bn. This missed the 6.50bn consensus estimate of the 9 analysts following the company. This was 12.32% below the prior year's 1st quarter results. View Full Interim Financials

Average growth rate-3.10%

AstraZeneca PLC had revenues for the full year 2012 of 27.97bn. This was 16.72% below the prior year's results. View Full Annual Financials

Average growth rate-2.63%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.



VIDEOS